Discover and read the best of Twitter Threads about #Piindustries
Most recents (4)
#PIIndustries is an established player in the Innovative Agro #CDMO space in India. They were planning to enter the Pharma CDMO space and have recently done some acquisitions as part of this plan through PI Health Sciences which is its wholly owned subsidiary for the Pharma space 
1. Acquisition 1:
-The company has acquired 100% stake in Therachem Research Medilab India Pvt Ltd and Solis Pharmachem which are the Indian subsidiaries of the American entity Therachem Research Medilab LLC.
-The company has acquired 100% stake in Therachem Research Medilab India Pvt Ltd and Solis Pharmachem which are the Indian subsidiaries of the American entity Therachem Research Medilab LLC.
-These acquisitions have been done at a consideration value of $42 million and $3 million respectively. The company has also acquired some of the assets of TRM US for a consideration of $5 million through its subsidiary PIHS LLC.
About -
Incorporated in 1947, PI Industries provides complex chemistry solutions in agri & pharma sciences. Over the years, the Co has successfully leveraged its capabilities across the Agri-sciences value chain by providing integrated and innovative solutions to its customers
Incorporated in 1947, PI Industries provides complex chemistry solutions in agri & pharma sciences. Over the years, the Co has successfully leveraged its capabilities across the Agri-sciences value chain by providing integrated and innovative solutions to its customers
by partnering with the best. Co has formed partnerships with leading companies globally where it provides solutions across the fields of R&D, regulatory services, manufacturing services, application development, marketing, distribution & customer connect initiatives.
#Piindustries Q3 Concall Highlights 🌱🧪
Like & Retweet for better reach!
Operational Highlights
1. Revenues stood at ₹1356 Cr, 17% growth YoY from ₹1162 Cr in Q3FY21
2. EBITDA grew by 8% YoY to ₹297 Cr
3. 19% growth in export business and 8% growth in domestic business
Like & Retweet for better reach!
Operational Highlights
1. Revenues stood at ₹1356 Cr, 17% growth YoY from ₹1162 Cr in Q3FY21
2. EBITDA grew by 8% YoY to ₹297 Cr
3. 19% growth in export business and 8% growth in domestic business
4. Overhead increased by 24% mainly attributed to increase in power and other utility cost
5. Hike in selling prices partially cover the incremental overheads and full impact to be reflected in next quarters
5. Hike in selling prices partially cover the incremental overheads and full impact to be reflected in next quarters
6. Gross margins stood at 46% and EBITDA margins at 22% for Q3FY22
7. Lower export incentives, partial cost pass through, etc. marginally impacted the gross margin despite favourable product mix
7. Lower export incentives, partial cost pass through, etc. marginally impacted the gross margin despite favourable product mix
Hello Traders, Below is our trade plan for upcoming week #NIFTY #BANKNIFTY #RELIANCE #INDIANCHEMICALS #TRADING #FNO #SENSEX #relianceagms2020 #FMCG
The list of stocks mentioned in the above list have recently crossed their All Time High #ATH #Momentum #Chemicals #Agrochem #FMCG #Telecom
Below is the link to chart where we have tried explaining the idea behind buy on Tata Consumer #Tataglobal #Tataconsumer #FMCG #Breakout #Momentum
tradingview.com/chart/TATACONS…
tradingview.com/chart/TATACONS…
